Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
October 03, 2018 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate...